Latest Advances in Heterocyclic Anticancer Compounds
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2450
Special Issue Editors
Interests: drug-DNA/HSA interaction; topoisomerase inhibition; antiproliferative activity of heterocyclic compound; acridine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Heterocyclic compounds have interesting structures and a wide spectrum of biological properties that have made them much-sought-after targets in the development of novel anticancer agents. The aim of this Special Issue is to concentrate on the latest advances in research into heterocyclic compounds and their potential anticancer properties. Based on the most up-to-date results, we propose that the work will offer an overview of antitumor chemotherapy. The biological activity of heterocyclic compounds is mainly attributed to the planarity of the aromatic structures, and it is noteworthy that the position and the nature of the substituents on the heterocyclic core are determinants for the biological properties and also for the observed selectivity. Recent research into the modes of action of these molecules suggests the likelihood of ongoing and exciting results and increased interest in this heterocyclic family. This Issue further pinpoints the latest progress in the development of anticancer agents based on naturally occurring and synthetic heterocycles, with detailed descriptions of in vitro/in vivo studies and clinical trial results.
Dr. Mária Kožurková
Dr. Rastislav Jendželovský
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Heterocyclic compounds
- Topoisomerase I and II
- Interaction of heterocyclic molecules with biomacromolecules
- Anticancer activity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
